S J Horning
Affiliation: Stanford University
- Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484Sandra J Horning
Stanford University, 875 Blake Wilbur Dr, Suite 2338, Stanford, CA 94305 5821, USA
J Clin Oncol 22:3032-8. 2004....
- Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 studySandra J Horning
Department of Medicine, Stanford University, CA, USA
Blood 115:775-7; quiz 918. 2010..This trial was registered at www.clinicaltrials.gov as #NCT00274924 [corrected]...
- Follow-up of adult cancer survivors: new paradigms for survivorship care planningSandra J Horning
Stanford University, Stanford, CA, USA
Hematol Oncol Clin North Am 22:201-10, v. 2008..Survivorship planning must become an integral part of every oncologist's education and practice...
- High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trialS J Horning
Department of Medicine, Divisions of Bone Marrow Transplantation and Medical Oncology, Stanford University Medical Center, Stanford, CA, USA
Blood 97:404-9. 2001....
- Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximabSandra J Horning
Stanford University, Stanford, CA 94305 5821, USA
J Clin Oncol 23:712-9. 2005....
- Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trialSandra J Horning
Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA 94304, USA
J Clin Oncol 20:630-7. 2002..To provide more mature data on the efficacy and complications of a brief, dose-intense chemotherapy regimen plus radiation therapy (RT) to bulky disease sites for locally extensive and advanced-stage Hodgkin's disease...
- Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphomaL J Johnston
Division of Bone Marrow Transplantation, Stanford University, California 94305, USA
Biol Blood Marrow Transplant 6:555-62. 2000..We conclude that HDSC/AHCT in refractory/recurrent NHL is associated with considerable acute and chronic toxicities. Given the toxicity profile, efficacy data were not sufficiently promising to warrant further study...
- Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trialR H Advani
Departments of Medicine Oncology, Stanford University Medical Center, 875 Blake Wilbur Drive, CC 2338, Stanford, CA 94305, USA
Ann Oncol 24:1044-8. 2013..Stanford V chemotherapy was administered for 8 weeks followed by radiation therapy (RT) 30 Gy to involved fields (IF). Freedom from progression (FFP), disease-specific survival (DSS) and overall survival (OS) were estimated...
- Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's diseaseM J Stuart
Division of Bone Marrow Transplantation, Stanford University Medical Center, California 94305 5623, USA
Biol Blood Marrow Transplant 7:552-60. 2001..This regimen demonstrated survival rates similar to those of historical studies that used the CBV regimen. However, the incidence of interstitial pneumonitis was in excess of expected...
- Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiationS J Horning
Department of Medicine, Stanford University Medical Center, CA, USA
J Clin Oncol 15:1736-44. 1997..The purpose of this study is to determine if VBM and regional radiotherapy can substitute for extended-field radiotherapy in favorable clinical stage (CS) I and II HD...
- Autologous hematopoietic cell transplantation in non-Hodgkin's lymphomaL J Johnston
Division of Bone Marrow Transplantation, Stanford University Medical Center, California, USA
Hematol Oncol Clin North Am 13:889-918. 1999..A large number of NHL patients succumb to their disease, so it is hoped that alternate therapies, such as cytokines, monoclonal antibodies, and vaccines, may improve the results of HDT...
- Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphomaSteven M Horwitz
Division of Oncology, Stanford University Medical Center, Ste 202, 1000 Welch Rd, Palo Alto, CA 94304, USA
Blood 103:777-83. 2004..Rituximab after HDT and HCT is feasible, and these phase 2 data support the current US Intergroup phase 3 trial in recurrent/refractory diffuse large cell lymphoma...
- Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492S J Horning
Department of Medicine, Stanford University Medical Center, Stanford, CA, USA
J Clin Oncol 18:972-80. 2000..This study was performed, in a multi-institutional setting, to evaluate the efficacy and feasibility of the Stanford V chemotherapy regimen plus radiotherapy to bulky Hodgkin's disease sites...
- High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphomaLisa Y Law
Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
Biol Blood Marrow Transplant 12:703-11. 2006..Patients who had required >3 previous chemotherapy regimens before HCT had an increased probability of relapse. CBV is an effective preparative regimen for patients with aggressive NHL who undergo allogeneic HCT...
- Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trialBradley C Ekstrand
Department of Medicine, Stanford University School of Medicine, Stanford, CA 94304, USA
Blood 101:4285-9. 2003..Further clinical trials are warranted to determine the optimal dosing schedule of rituximab, the potential for combination treatment, and the possible relationship of rituximab treatment to the development of LCL...
- Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary originOlga K Weinberg
Department of Pathology, Stanford University Medical Center, Stanford Comprehensive Cancer Center, Stanford, CA 94305, USA
Am J Surg Pathol 33:591-8. 2009..019) and disease-specific survival (P=0.006) in comparison with the t(14;18)-negative group. In low stage FL, the status of t(14;18) seems to be more predictive of outcome than origin from an extranodal versus nodal site...
- Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experienceAndy I Chen
Stanford University Medical Center, Division of Blood and Marrow Transplantation, Stanford, California 94305, USA
Biol Blood Marrow Transplant 14:741-7. 2008....
- Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's diseaseRanjana Advani
Stanford University Comprehensive Cancer Center, Stanford, CA 94305, USA
J Clin Oncol 25:3902-7. 2007..To correlate [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) status after chemotherapy, but before radiation, with outcome in patients treated with the Stanford V regimen...
- Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporineRanjana Advani
Stanford University Medical Center, Stanford, CA 94305 5821, USA
Leuk Lymphoma 48:521-5. 2007..By interrupting T-cell activation, CsA may alter the immune dysregulation that characterizes AILT. The efficacy of CsA is being explored in patients with recurrent AILT in a prospective trial (ECOG 2402)...
- Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphomaWen Kai Weng
Division of Blood and Marrow Transplantation, 300 Pasteur Dr, Rm H3249, Stanford University School of Medicine, Stanford, CA 94305, USA
J Clin Oncol 28:279-84. 2010..In the current report, we determine whether FcgammaR polymorphisms are correlated with clinical outcomes in 33 patients with B-cell non-Hodgkin's lymphoma who received post-transplantation rituximab...
- Management of advanced stage Hodgkin lymphomaRanjana Advani
Stanford University Medical Center, Stanford, California 94305, USA
J Natl Compr Canc Netw 4:241-7. 2006....
- Screening for coronary artery disease after mediastinal irradiation for Hodgkin's diseasePaul A Heidenreich
Department of Medicine, Division of Cardiology, Stanford University Medical Center, Stanford, CA, USA
J Clin Oncol 25:43-9. 2007..The objective of this study was to evaluate whether stress imaging can identify severe, unsuspected coronary stenoses in patients who had prior mediastinal irradiation for Hodgkin's disease...
- Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphomaSally Arai
Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
Biol Blood Marrow Transplant 16:1145-54. 2010..This new transplant regimen for HL resulted in decreased BCNU toxicity with encouraging FFP and OS. A prospective, risk-modeled comparison of this new combination with other conditioning regimens is warranted...
- Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapyRanjana Advani
Division of Oncology, Department of Medicine, Stanford University Medical Center, 875 Blake Wilber Drive, Stanford, CA 94305, USA
J Clin Oncol 22:1454-9. 2004....
- Utility of influenza vaccination for oncology patientsDaniel A Pollyea
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
J Clin Oncol 28:2481-90. 2010....
- Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic inRanjana H Advani
Stanford University, Stanford, CA 94305, USA
Br J Haematol 151:143-51. 2010..The prognostic discrimination provided by the E-IPI for low and low-intermediate elderly DLBCL patients needs validation by other datasets...
- Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysisKristen N Ganjoo
Department of Medicine Oncology, Stanford University, CA, USA
Leuk Lymphoma 47:998-1005. 2006..In this patient population, treatment with RA-CHOP did not result in any episodes of grade 3 or 4 proteinuria, heart failure or hemorrhage. The RA-CHOP combination was generally well tolerated and safe...
- Rituximab in stem cell transplantation for aggressive lymphomaSteven M Horwitz
Oncology and Bone Marrow Transplantation, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Curr Hematol Rep 3:227-9. 2004
- Future directions in radioimmunotherapy for B-cell lymphomaSandra J Horning
Division of Oncology, Stanford University School of Medicine, Palo Alto, CA 94304, USA
Semin Oncol 30:29-34. 2003....
- Lymphocyte predominant Hodgkin's diseaseBradley C Ekstrand
Division of Oncology, Department of Medicine, Stanford University School of Medicine, 1000 Welch Road, Suite 202, Palo Alto, CA 94304, USA
Curr Oncol Rep 4:424-33. 2002..Recent insights into the molecular pathogenesis of LPHD and the development of novel targeted therapies promise to improve future treatment...
- Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximabY Natkunam
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
Clin Lymphoma 2:185-7. 2001..We present an unusual case of a 30-year-old man with recurrent TCRBCL arising from lymphocyte-predominant Hodgkin's disease with remarkable response to treatment with the anti-CD20 antibody, rituximab...
- Hodgkin's diseaseBradley C Ekstrand
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
Blood Rev 16:111-7. 2002..Patients who relapse now have a more favorable prognosis with the availability of active salvage regimens, autologous stem cell transplantation, and novel biologic agents...
- Lymphocyte predominant Hodgkin's disease: more patience than patientsBradley C Ekstrand
Department of Medicine, Stanford University School of Medicine, California 94304, USA
Cancer J 8:367-8. 2002
- Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's diseaseHolbrook Kohrt
Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA
Oncol Res 18:287-92. 2009..Our observation challenges prior belief that patients with HD remain immunodeficient following therapy and argues that the clinical significance of the EBV-specific immune response in EBV-negative HD should be further investigated...
- Something old, something few, something subjective, something déjà vuSandra J Horning
J Clin Oncol 21:1-2. 2003
- Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology GroupRalph M Meyer
Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada
J Clin Oncol 23:4634-42. 2005..We report results of a randomized trial comparing ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy alone with treatment that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma...
- Revised response criteria for malignant lymphomaBruce D Cheson
Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
J Clin Oncol 25:579-86. 2007..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
- Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyJane N Winter
Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Blood 107:4207-13. 2006..Our finding that Bcl-6(+) cases did not benefit from the addition of R to CHOP requires independent confirmation...
- Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphomaThomas M Habermann
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 24:3121-7. 2006....
- FDG-PET lymphoma demonstration project invitational workshopGary J Kelloff
National Institutes of Health NIH National Cancer Institute NCI Division of Cancer Treatment and Diagnosis DCTD Cancer Imaging Program, Bethesda, MD, USA
Acad Radiol 14:330-9. 2007....
- Optimizing rituximab in B-cell lymphomaSandra J Horning
J Clin Oncol 23:1056-8. 2005
- Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public WorkshopRobert C Bast
M D Anderson Cancer Center, Houston, TX, USA
Gynecol Oncol 107:173-6. 2007....
- Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497Timothy M Kuzel
Feinberg School of Medicine Northwestern University, Chicago, IL 60611, USA
Leuk Lymphoma 48:2397-402. 2007..Toxicities were generally grade I - II and transient but 1 patient experienced a fatal thrombo-embolism. Therapy with DD is tolerable and modest efficacy was observed in SLL subtype. Measured IL-2R status did not correlate with efficacy...
- Burkitt's lymphoma--the message from microarraysNancy Lee Harris
N Engl J Med 354:2495-8. 2006
- Follicular lymphoma, survival, and rituximab: is it time to declare victory?Sandra J Horning
J Clin Oncol 26:4537-8. 2008